648 related articles for article (PubMed ID: 13679867)
1. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
2. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN expression leading to high Akt activation in human multiple myelomas.
Hyun T; Yam A; Pece S; Xie X; Zhang J; Miki T; Gutkind JS; Li W
Blood; 2000 Nov; 96(10):3560-8. PubMed ID: 11071655
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
Tabellini G; Cappellini A; Tazzari PL; Falà F; Billi AM; Manzoli L; Cocco L; Martelli AM
J Cell Physiol; 2005 Feb; 202(2):623-34. PubMed ID: 15316930
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
7. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
8. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
Ge NL; Rudikoff S
Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
[TBL] [Abstract][Full Text] [Related]
9. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Tu Y; Gardner A; Lichtenstein A
Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
[TBL] [Abstract][Full Text] [Related]
12. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Kim S; Domon-Dell C; Wang Q; Chung DH; Di Cristofano A; Pandolfi PP; Freund JN; Evers BM
Gastroenterology; 2002 Oct; 123(4):1163-78. PubMed ID: 12360479
[TBL] [Abstract][Full Text] [Related]
13. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.
Jiang BH; Jiang G; Zheng JZ; Lu Z; Hunter T; Vogt PK
Cell Growth Differ; 2001 Jul; 12(7):363-9. PubMed ID: 11457733
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
J Neurosurg; 2003 Jan; 98(1):154-61. PubMed ID: 12546364
[TBL] [Abstract][Full Text] [Related]
16. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway.
Wan X; Yokoyama Y; Shinohara A; Takahashi Y; Tamaya T
Cell Death Differ; 2002 Apr; 9(4):414-20. PubMed ID: 11965494
[TBL] [Abstract][Full Text] [Related]
17. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
18. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
19. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY
Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062
[TBL] [Abstract][Full Text] [Related]
20. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]